Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.
OncoScint (Cytogen Corp, Lonza Biologics): Full Drug Profile
Medically reviewed by Min Clinic Staff | Updated: January 2026
OncoScint (Cytogen Corp, Lonza Biologics) - General Information
Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors.
Pharmacology of OncoScint (Cytogen Corp, Lonza Biologics)
Binds to the tumor associated glycoprotein 72 antigen, which is a cell surface protein generally over-expressed in colorectal cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of TAG-72 expressing cells and tumors
Additional information about OncoScint (Cytogen Corp, Lonza Biologics)
- OncoScint (Cytogen Corp, Lonza Biologics) Indication
For diagnosis of extrahepatic malignant cancers
- Mechanism Of Action
- Binds selectively to cell-surface TAG-72 expressed on colorectal tumors.
- Generic Name
- Satumomab Pendetide
- Drug Category
- Imaging Agents
- Drug Type
- Biotech; Approved
- Other Brand Names containing Satumomab Pendetide
- OncoScint (Cytogen Corp, Lonza Biologics);
- Biotransformation
- Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
- Half Life
- 0.8 hours (mammalian reticulocytes, in vitro)
- Chemical IUPAC Name
- Murine anti-TAG72 antibody conjugated with Indium 111
- Chemical Formula
- C6268H9708N1666O1971S48
- Organisms Affected
- Humans and other mammals